Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE
Risk for recurrent venous thromboembolism reduced for patients with isolated distal DVT receiving six additional weeks of rivaroxaban
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.